Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI EV-to-FCF is -0.90 as of Jul. 23, 2026. The stock has 3 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Verici Dx ranks worse than 1010100% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Verici Dx's Enterprise Value is £5.65 Mil.
Verici Dx's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £-6.28 Mil. Therefore, Verici Dx's EV-to-FCF for today is -0.90.
The historical rank and industry rank for Verici Dx's EV-to-FCF or its related term are showing as below:
LSE:VRCI'
s EV-to-FCF Range Over the Past 10 Years
Min: -3 Med: -0.54 Max: 0.35
Current: -0.9
During the past 6 years, the highest EV-to-FCF of Verici Dx was 0.35. The lowest was -3.00. And the median was -0.54.
LSE:VRCI's EV-to-FCF is ranked worse than 100% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.2
vs LSE:VRCI: -0.90
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Verici Dx's share price for today is £0.0035.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Verici Dx EV-to-FCF Related Terms
Verici Dx EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Verici Dx's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Verici Dx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Verici Dx's EV-to-FCF falls into.
Verici Dx's current Enterprise Value is £5.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £-6.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (LSE:VRCI) has a EV-to-FCF of -0.90 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Verici Dx and its competitors. According to the industry distribution chart, Verici Dx ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry.
Is Verici Dx's EV-to-FCF too high?
Verici Dx's current EV-to-FCF is -0.90. Based on the distribution chart, Verici Dx ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Verici Dx's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #999999 out of 99 companies for EV-to-FCF. This places Verici Dx in the lower half of its industry. The industry median EV-to-FCF is 26.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.20, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current EV-to-FCF is -0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current EV-to-FCF of -0.90. The current EV-to-FCF is -0.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current EV-to-FCF is -0.90 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
